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ABSTRACT OF THESIS 
THE EFFECTS OF CURCUMIN AND FENUGREEK SOLUBLE FIBER ON THE 
PHYSICAL WORKING CAPACITY AT THE FATIGUE THRESHOLD, PEAK 
OXYGEN CONSUMPTION, AND TIME TO EXHAUSTION  
Curcumin, a polyphenol, has been suggested to improve metabolic byproduct 
clearance and increase nitric oxide production in working muscle. These purported 
effects may delay neuromuscular fatigue. Therefore, the purpose of this study was to 
examine the effects of curcumin in combination with fenugreek (CUR) or fenugreek 
soluble fiber alone (FEN) on the neuromuscular fatigue threshold (PWCFT), time to 
exhaustion (Tlim) on a graded exercise test (GXT), and ?̇?O2peak in untrained subjects. 
Forty-seven, college-aged, aerobically untrained individuals were randomly assigned to 
one of three supplementation groups; placebo (PLA, n=15), curcumin + fenugreek, 
CurQfen® (CUR, n=18), or fenugreek soluble fiber (FEN, n=14). All subjects performed 
a maximal GXT on a cycle ergometer to determine the PWCFT, Tlim, and V̇O2 peak before 
(PRE-test) and after (POST-test) 28 days of daily supplementation. Statistical analyses 
included 3 separate, one-way ANCOVAs to determine if there were any differences 
among the groups (PLA, CUR, FEN) for adjusted post-test scores for the PWCFT, 
V̇O2peak, and Tlim. The respective pre-test score was used as the covariate. In addition, 
reliability analyses (PRE- to POST-test) for the PLA group were used to calculate the 
minimal difference needed to be real (MD). The adjusted POST PWCFT values showed 
no statistical differences between groups (F= 3.141p= 0.053); however pairwise LSD 
comparisons indicated a significant difference between the CUR and PLA groups (p= 
0.016), but not between the CUR and FEN groups. Therefore, separate one-way 
ANCOVAs were used to examine the adjusted PWCFT means for the PLA vs. CUR (F = 
4.906, p =0.035) and the PLA vs. FEN (F = 2.969, p = 0.097). The one- way ANCOVA 
for ?̇?O2 peak (F= 0.612 p= 0.547) and Tlim (F = 0.688, p = 0.508) values showed no 
statistical difference among the groups. Individual responses in each group showed ~ 
20% of subjects in the CUR group, ~ 7% in the FEN group, and ~6% in the PLA group 
had values greater than the MD for the PWCFT, but none of the subjects in the PLA, FEN, 
or CUR groups exceeded the MD for ?̇?O2 peak or Tlim. These findings indicated 
CurQfen® supplementation increased the PWCFT compared to a placebo, but not 
compared to fenugreek soluble fiber alone. However, there were no effects of CurQfen® 
on V̇O2 peak or Tlim. The mechanisms responsible for delaying time to neuromuscular 
fatigue may include increased NO production and increased blood flow to remove 
metabolic byproducts; however, the cellular changes which could lead to increases in Tlim
and ?̇?O2 peak may not have been sensitive to the GXT protocol or the given dosage of 
curcumin supplementation.  Considering individual responses, CurQfen® 
supplementation resulted in a real change in the PWCFT for a small portion of the subjects 
(~20%). These findings suggested that CurQfen® supplementation without exercise 
training may help to improve time to neuromuscular fatigue in certain individuals, but the 
group mean analyses were not necessarily reflective of the responses for a majority of the 
subjects.  
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CHAPTER 1. INTRODUCTION 
Curcumin is an active ingredient of polyphenolic curcuminoids, which are found 
in the spice turmeric (Boonla et al. 2014). Curcumin has been well studied in clinical 
investigations over the last few decades and has been shown to have anti-inflammatory, 
anti-cancer, anti-diabetic, anti-hypertensive, anti-dementia and antioxidant properties 
(Boonla et al. 2014). Many of the purported effects of curcumin are related to reducing 
oxidative stress as well as improving markers of vascular function and cardiac 
performance in animal models (Boonla et al. 2014). Recent studies, however, have also 
demonstrated that curcumin supplementation may increase blood antioxidant capacity 
and reduce exercise-induced oxidative stress in humans (Takahashi et al. 2013). 
Specifically, curcumin supplementation has been shown to offset muscle damage and 
functional deficits associated with the eccentric nature of downhill running (Davis et al. 
2007). Previous investigators have reported decreased markers of muscle damage, 
including inflammatory cytokines and creatine kinase after curcumin supplementation 
compared with a placebo (Davis et al. 2007). These decreases in inflammatory markers 
may have offset some of the performance deficits associated with eccentric exercise-
induced muscle damage (Davis et al. 2007).   
Recently, curcumin has been shown to decease the accumulation of metabolic 
byproducts such as lactate and ammonia (Sahin et al. 2016) during acute exercise bouts. 
Specifically, it was reported (Sahin et al. 2016) that decreased levels of lactate and 
muscle malondialdehyde were associated with increased run times to exhaustion in 
rodents supplemented with curcumin compared to a placebo. It was suggested that the 
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increased clearance of metabolic byproducts with curcumin supplementation might 
potentially be linked to increased production of nitric oxide (NO), a potent vasodilator, 
and the subsequent vasodilatory response (Boonla et al 2014). Thus, previous research 
(Boonla et al. 2014, Sahin et al. 2016, Takahashi et al. 2013) has shown the potential for 
curcumin to have a wide spectrum of bioactivities that may promote health as well as 
improve endurance performance. There are currently limited data, however, regarding the 
effects of curcumin supplementation on submaximal and maximal exercise performance 
in humans (Boonla et al. 2014).  
The physical working capacity at the fatigue threshold (PWCFT) is an 
electromyographic (EMG) technique that theoretically estimates the highest power output 
that can be maintained for an extended period of time without evidence of neuromuscular 
fatigue (deVries et al 1987, 1990). Specifically, during a continuous incremental test, the 
PWCFT is defined as the average of the highest power output that results in no significant 
change in EMG amplitude (a nonsignificant slope coefficient) and the lowest power 
output that results in a significant increase in EMG amplitude (a significant positive slope 
coefficient) (deVries et al 1987, 1990). An important contributing factor to the etiology 
of neuromuscular fatigue is the accumulation of various metabolic byproducts and/or ions 
(i.e., inorganic phosphate, hydrogen ions, ammonia and potassium) (Camic et al 2010, 
Zuniga et al 2010, Bergstrom et al 2013) that interfere with skeletal muscle contractile 
mechanism and propagation of the action potential along the sarcolemma (Clausen 2013, 
Enoka and Stuart 1992, Gladden 2004, MacLaren et al 1989, Robergs et al 2004, 
Westerblad et al 2002). Previously, investigators (Camic et al. 2010) examined the effects 
of daily oral administration of arginine-based supplements for 4 weeks on the PWCFT in 
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aerobically untrained men. Like curcumin, one of the physiological actions of arginine is 
to up regulate nitric oxide (NO) production and increase endothelium-dependent 
vasodilation (Boonla 2014). The authors (Camic et al. 2010) reported significant 
increases in the PWCFT after supplementation with arginine compared to a placebo. Thus, 
it is possible that curcumin supplementation may work similarly to arginine to delay the 
onset of neuromuscular fatigue and the PWCFT through NO-mediated vasodilation 
(Boonla et al. 2014) and improved metabolic byproduct clearance (Sahin et al 2016). 
Previous investigators (Sahin et al. 2016) have reported increased run times to 
exhaustion in rodents supplemented with curcumin compared to a placebo. Consistent 
with the findings by Sahin et al. (2016), Huang et al. (2015) reported that curcumin 
supplementation dose-dependently increased grip strength and endurance performance 
compared to the vehicle treatment (Huang et al 2015). Furthermore, previous 
investigators have shown that curcumin supplementation, in combination with endurance 
training, has the potential to accelerate mitochondrial biogenesis in skeletal muscle by 
increasing cAMP levels (Hamidie et al 2015). Peripheral cellular changes, such as 
increased mitochondrial density, have been shown to improve submaximal performance, 
(Basset 2000). Thus, it is possible the cellular effects of curcumin to improve markers of 
aerobic respiration may also delay time to fatigue and improve maximal oxygen 
consumption (V̇O2) during incremental exercise. 
Curcumin has poor absorption into the intestines and consequently low 
bioavailability in the blood, and thus has been combined with other compounds to 
improve absorption and increased blood concentration levels (Krishnakumar et al 2012). 
One ingredient that has been studied in combination with curcumin is the naturally 
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growing plant, fenugreek soluble fiber (Krishnakumar et al 2012). The galactomannan 
component of fenugreek has been combined with curcumin (CurQfen®) to increase 
absorption from the small intestine (Krishnakumar et al 2012). Galactomannan is a 
soluble fiber guar gum, and a potential active component of fenugreek seeds 
(Srichamroen et al 2008). Specifically, galactomannans from fenugreek have been shown 
to have increased effects on glycemic and lipidemic status in rats (Srichamroen et al 
2008). Thus, it is possible the fenugreek component in CurQfen® may increase FFA 
release and decrease insulin levels, supporting improvements in submaximal exercise 
performance markers. No previous studies, however, have examined the effects of 
supplementation with curcumin in combination with fenugreek soluble fiber or fenugreek 
soluble fiber alone on submaximal or maximal indices of endurance performance. 
Therefore, the purpose of this study was to examine the effects of curcumin in 
combination with fenugreek (CUR) or fenugreek soluble fiber alone (FEN) on the 
neuromuscular fatigue threshold (PWCFT), time to exhaustion (Tlim) on a graded exercise 
test (GXT), and ?̇?O2peak in untrained subjects. Based on the results of previous studies 
(Boonla et al. 2014, Sahin et al. 2016, Takahashi et al. 2013), it was hypothesized that 
curcumin supplementation would delay the onset of neuromuscular fatigue and increase 
the PWCFT as well as increase Tlim and ?̇?O2peak compared to a placebo.  
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CHAPTER 2. REVIEW OF LITERATURE 
2.1 Curcumin: Mechanisms of Action 
 Boonla et al. (2014) 
Previous studies have shown that increased production of oxidants, reduced nitric 
oxide (NO) bioavailability, and reduced activity of antioxidants in the vascular system 
are involved in hypertension and cardiovascular disease. Research has found that 
polyphenols play an important role in the maintenance of health and prevention of 
diseases. Curcumin is an active ingredient of polyphenolic curcuminoids extracted from 
the rhizomes of the spice turmeric. Curcumin is well known for its anti-inflammatory, 
anti-cancer, anti-diabetic, anti-hypertensive, anti-dementia and antioxidant properties and 
recent studies have shown that curcumin reduces oxidative stress in rodent models. 
However, there have been no reports about the activity of curcumin in 2kidney-1clip (2K- 
1C)-induced hypertension-induced endothelial dysfunction and vascular remodeling. 
Therefore, the present study was designed to investigate the effects of curcumin on 2K-
1C - induced hypertension, endothelial dysfunction, vascular remodeling and oxidative 
stress in male rats. The experimenters randomly placed the rats into the sham operated 
groups or 2K-1C groups. Hypertension was induced by clipping the left renal artery with 
a silver clip in groups 3-5. Group 1 rats were sham operated and received the control, 
propylene glycol, and group 2 sham operated rats received 100 mg/kg/day of curcumin. 
Groups 3–5 were clipped rats that received propylene glycol alone, 50 mg/kg/day of 
curcumin and 100 mg/kg/day, respectively. After 6 weeks of treatment, the authors found 
that curcumin ameliorated hemodynamic performance in 2K-1C hypertensive rats, by 
reducing blood pressure, increasing hindlimb blood flow and decreasing hindlimb 
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vascular resistance. The results also showed that curcumin attenuated hypertension-
induced oxidative stress and vascular structural modifications. Overall, the authors 
concluded that the mechanisms responsible for the antihypertensive action of curcumin in 
2K-1C hypertension- induced endothelial dysfunction and vascular remodeling involve 
the improvement of nitric oxide bioavailability and a reduction in oxidative stress.  
Sahin et al. (2016) 
The purpose of this study was to investigate the effects of curcumin 
supplementation on oxidative stress markers, exercise endurance, performance, and 
changes in serum and muscle proteins in rats following a test to exhaustion. This study 
used 28 male rats, assigned to one of four different treatment groups 1) control, 2) no 
exercise + curcumin supplement, 3) exercise only 4) exercise + curcumin 
supplementation. Supplementation was administered every day for 6 weeks in the form of 
100 mg·kg-1 CurcuWin oral tablets. The rodents completed a 6-week exercise period in 
which they exercised on a motor driven rodent treadmill 5 days a week for 45 minutes at 
a rate of 25 m·min-1. Following the 6-week exercise protocol, the rats were sacrificed and 
blood and muscle samples were analyzed for muscle markers, oxidative stress, and 
antioxidant markers. The results showed there were decreased levels of lactate and 
muscle malondialdehyde in the treatment groups which received the curcumin 
supplement. The run time to exhaustion also improved in the supplement groups and 
muscle nuclear factor and heat shock protein levels were significantly lower in group 4 
(exercise + curcumin). The results of this study suggested that curcumin may have the 
ability to help prevent muscle damage during exercise by regulating certain proteins, 
which can lead to increased endurance and exercise performance.  
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Takahashi et al. (2013) 
The purpose of this study was to investigate the effects of curcumin 
supplementation on exercise-induced oxidative stress (reactive oxygen species [ROS]) in 
humans. Ten untrained male subjects (23-30 years of age) were included in this study. 
Prior to supplementation, the subjects performed a baseline test to determine the VO2 
max. Each subject then participated in 3 laboratory- based trials in a randomized order: 
(1) placebo (control), (2) single curcumin supplementation (90 mg only before exercise)
and (3) double curcumin supplementation (90 mg before and immediately after exercise). 
A washout period of at least one week was included between each condition trial. For 
each trial, the subjects exercised at 65% of their VO2max for 60 minutes. Blood samples 
were taken pre-exercise, immediately after, and 2 hours post exercise. The results showed 
that the curcumin supplementation trials had decreased exercise-induced serum 
concentrations of d-ROMs and TRX-1 and increased serum BAP concentrations and 
plasma GSH after exercise. There were no changes in heart rate or RPE among the three 
trials. These findings suggested that curcumin supplementation may increase blood 
antioxidant capacity, and, therefore help to decrease exercise-induced oxidative stress. 
Summary 
Curcumin, an active ingredient of polyphenolic curcuminoids extracted from the 
rhizomes of the spice turmeric is well known for its an anti-inflammatory, anti-cancer, 
anti-diabetic, anti-hypertensive, anti-dementia and antioxidant properties (Boonla et al 
2014). Recently, curcumin has also been shown to decrease hypertension- induced 
oxidative stress and vascular structural modifications (Boonla et al. 2014). Curcumin has 
also shown to reduce blood pressure, increase hindlimb blood flow, and decreasing 
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hindlimb vascular resistance in mice. In addition, curcumin supplementation has been 
shown to improve NO bioavailability and reduce oxidative stress (Boonla et al. 2014), A 
study by Takahashi et al. (2013) showed that curcumin also has physiological effects on 
human subjects as well, including decreased exercise-induced oxidative stress. These 
findings extended those of the rodent study by Boonla et al. (2014) and suggested 
curcumin may have the potential to improve endurance performance in humans 
(Takahashi et al. 2013).  
2.2 Physiological and Performance Effects of Curcumin supplementation 
Davis et al. (2007) 
The purpose of this study was to investigate the effects of curcumin 
supplementation on muscle damage and functional deficits associated with downhill 
running in rodents. The heavy eccentric muscle contraction in downhill running has been 
linked to increased muscle fiber damage, inflammation, and delayed onset muscle 
soreness (DOMs) as well as several other functional deficits. The mice used in this study 
were randomly assigned to one of four groups, 1) downhill running + placebo, 2) 
downhill running + curcumin, 3) uphill running + placebo, or 4) uphill running + 
curcumin. The “control” in this study was the uphill running group, since it has been 
shown to produce little to no muscle damage and inflammation. Previous studies have 
shown that voluntary and involuntary running in rodents was significantly decreased 
following a downhill run for up to 4 days. The suggested reasoning behind this decrease 
in performance is due to inflammation including increases in brain IL-1 associated with 
downhill running. The authors hypothesized that the anti-inflammatory activity of 
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curcumin would decrease recovery time following a downhill run and increase running 
performance due to a reduction in inflammation-induced deficits in regeneration of 
muscle fibers, soreness, and central nervous system fatigue. Curcumin supplementation 
was administered to the mice in the form of a food pellet containing 10 mg of curcumin 
powder (Down-Cur and Up-Cur), and the placebo groups were fed a food pellet without 
curcumin (Down-Plac and Up-Plac)] every day for 3 days prior to the up/downhill run. 
Following supplementation, the mice performed their initial uphill/downhill run tests. 
Two groups of mice (Down-Plac and Down- Cur) ran on a rodent treadmill at -14% grade 
and the other two groups (Up- Plac and Up- Cur) ran at a +14% grade at a rate of 
22m/min for 150 minutes. Following the uphill/downhill runs, a subset of mice were used 
to assess recovery of running performance. These mice ran to fatigue on a motorized 
treadmill at 36 m/min and 8% grade at either 48 or 72 h post-up/downhill run. A second 
subset of mice were used to assess recovery of voluntary activity following the 
up/downhill run on the rodent treadmill. Voluntary wheel running activity during the 
“active” dark period was measured automatically for 7 consecutive days. The results 
showed that downhill running was in fact associated with an increase in inflammatory 
cytokines and creatine kinase, however, the increase in these metabolic byproducts were 
offset in the group that received the curcumin supplement. The groups who received the 
curcumin supplement also showed increased voluntary run times as compared to those 
who received the placebo and the groups who participated in the involuntary run. The 
importance of these results suggest that the anti-inflammatory phytochemical curcumin 
can decrease recovery time following high intensity eccentric exercise, known to produce 
muscle damage and DOMS. Curcumin also appears to be capable of enhancing a 
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behavioral response (spontaneous running), which implied an important central nervous 
system component (e.g., drive, motivation) that may be related to less pain and reduced 
inflammatory cytokines.   
Huang et al. (2015) 
The aim of this study was to evaluate the potential benefits of curcumin 
supplementation in a mouse model on physical performance test and exhaustive 
swimming. The authors hypothesized that curcumin supplementation may mediate 
exercise-induced metabolites, energy distribution, and even improve physical 
performance. This experiment used male mice, which were randomly placed into one of 
four groups to receive treatment by oral gavage: placebo control (water), curcumin 
supplement at 12.3 mL·kg-1·day-1, 24.6 mL·kg-1·day-1, and 61.5 mL·kg-1·day-1. The 
supplementation period lasted a total of 28 days. Each mouse subject was tested for its 
forelimb grip strength, and completed an exhaustive swimming test to evaluate 
performance and time to fatigue. The physical fatigue-associated biomarkers included, 
serum lactate, ammonia, blood urea nitrogen (BUN), and glucose and tissue damage 
markers such as aspartate transaminase (AST), alanine transaminase (ALT), and creatine 
kinase (CK). The results of this study showed a dose-dependent response for curcumin 
supplementation on increased grip strength and endurance performance and significantly 
decreased lactate, ammonia, BUN, AST, ALT, and CK levels post exercise. Muscular 
glycogen content, an important energy source for exercise, was also significantly 
increased in the groups who received the curcumin supplement as compared to the 
placebo. From these results, the authors concluded that curcumin supplementation may 
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have a wide spectrum of bioactivities for promoting health, improving exercise 
performance, and preventing fatigue.  
Summary: 
Recent studies have observed the physiological and performance effects of 
curcumin supplementation, particularly in animal subjects. Davis et al. (2007) reported 
increased voluntary run times for those mice receiving the curcumin supplement 
compared to those who received the placebo. These results suggested that the anti-
inflammatory phytochemical curcumin can decrease recovery time following high 
intensity eccentric exercise, known to produce the most muscle damage and DOMS. 
Interestingly, due to the increased voluntary run times, curcumin appears to be capable of 
enhancing a behavioral response, which implies an important central nervous system 
component (e.g., drive, motivation) that may be related to less pain and perhaps reduced 
inflammatory cytokines (Davis et al. 2007). Curcumin supplementation also has an effect 
on lactate, ammonia, BUN, AST, ALT, and CK  (physical fatigue-associated biomarkers) 
levels post exercise. Huang et al. (2015) found a significant decrease in the levels of these 
metaoblites (lactate, ammonia, etc.) post exercise in the subjects given curcumin 
supplementation compared with a placebo. The authors (Huang et al. 2015) also reported 
increased grip strength and endurance performance among the supplemented groups. 
Muscular glycogen content, an important energy source for exercise, was also 
significantly increased in the groups who received the curcumin supplement as compared 
to the placebo (Huang et al. 2015). From the results of these studies (Davis et al. 2007, 
Huang et al. 2015), it appears that curcumin supplementation may have a wide spectrum 
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of bioactivities for promoting health, improving exercise performance, preventing 
fatigue, and even a potential CNS component.  
2.3 Timing and Dosage of Curcumin Supplementation 
Krishnakumar et al. (2012) 
Curcumin has been shown to have many positive physiological actions and has 
shown not to be toxic even at very high doses of 8–12 g/day, however, despite the safety, 
efficacy, and well-tracked mechanisms of action, curcumin has poor systematic 
bioavailability upon oral administration due to inadequate intestinal absorption, rapid 
metabolism and short half-life. The low bioavailability of curcumin limits its use as a 
therapeutic agent, therefore the purpose of this study was to investigate the bioavailability 
of curcumin combined with the spice fenugreek as a vehicle for administration in animals 
and humans. 8 human male subjects participated in this study. Each subject was tested 
with the unformulated and formulated curcumin supplements. For the first test, each 
subject was first given two capsules of 500 mg of unformulated curcumin and 2 ml blood 
sample were withdrawn at 0, 0.5, 1, 3, 5, 8 and 24 h post-dose for analysis. After 1 week 
of curcumin feeding, the subjects were given three capsules of 500 mg containing newly 
formulated curcumin supplement (containing curcumin and fenugreek) and the same 
protocol was repeated (the dosage of the three formulated capsules was equivalent to 600 
mg of curcumin). The same was repeated again after 1 week with 250 mg formulated 
supplement and the blood samples were withdrawn for analysis (the 250mg dosage was 
equivalent to 100mg of unformulated curcumin). The results of this study found that in 
humans, the absorption of curcumin + fenugreek supplement was 15.8 times higher in 
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oral dosages of 1500 mg (equivalent to 600 mg curcumin), 12.9 times higher at 250 mg 
(equivalent to 100 mg curcumin) of CGM as compared to 1000 mg of unformulated 
curcumin. These results indicate that the bioavailability of curcumin is not only increased 
by combining it with fenugreek, but is also dose dependent. 
Summary: 
The observed physiologic effects of curcumin and its use as a therapeutic agent 
have been limited due to its poor systematic bioavailability upon oral administration 
which is related to its inadequate intestinal absorption, rapid metabolism, and short half-
life. Krishnakumar et. al. (2012) investigated the bioavailability of curcumin combined 
with the herb fenugreek in animals and humans. In the human subjects who received the 
formulated curcumin supplement, absorption was 15.8 times higher in oral dosages of 
1500 mg (equivalent to 600 mg curcumin), and 12.9 times higher at 250 mg (equivalent 
to 100 mg curcumin) as compared to 1000 mg of unformulated curcumin. The results of 
this study indicate that the bioavailability of curcumin is dose dependent and increased by 
combining it with fenugreek.  
2.4 Development of the Physical Working Capacity at the Fatigue Threshold Model 
deVries et al. (1982) 
This study examined the relationship between two fatigue thresholds (critical 
power [CP] and fatigue threshold [FT]), derived from unique methodologies. The CP was 
determined from four, exhaustive, constant power output cycle ergometer workbouts. The 
CP was defined as the slop of the relationship between the total work performed and the 
time to exhaustion for the four workbouts. In addition, the anaerobic threshold (AT) was 
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determined from gas exchange and ventilatory parameters measured during an 
incremental test to exhaustion. The FT was then estimated by measuring integrated 
electromyographic amplitude (IEMG) from the  quadriceps femoris muscle during four, 
constant power output cycle ergometer workbouts. This study utilized a unipolar lead 
system, with surface electrodes placed on the lateral portion of the dominant quadriceps 
femoris muscle and reference electrode over the anterior superior iliac spine (ASIS). The 
IEMG data was plotted over 10 second periods as a function of time during three or four 
workbouts of various power outputs on the cycle ergometer. The slope coefficients from 
each power output were determined and then power output was plotted against the slope 
coefficients for each of three or four workbouts (fatigue slope coefficient on the x axis 
and power output in W on the y). The FT was identified as the point of zero slope, 
estimated from the Y intercept value and expressed in W. The FT was defined as the 
highest constant power output that could be maintained during cycle ergometry without 
an increase in IEMG activity. This study demonstrated a linear relationship between time 
and increased IEMG activity (r2  = 0.88-0.99). The FT ranged from 124-284W, with a 
mean value of 190.5 ± 14.0 W. In addition, the CP and FT as well as the AT and FT were 
compared. They found that the relationship between AT and FT (r = 0.903, p<0.001) was 
stronger than that between FT and CP (r= 0.860, p<0.001) and there was no significance 
between AT and FT, CP was less than FT. The authors concluded that due to the 
correlation found among the three variables, CP, AT and FT there may be a single 
phenomenon that underlies them all, and IEMG estimation of FT may provide an 
alternative to the measurement of AT. 
15 
deVries et al. (1987) 
The purpose of this study was to develop a test utilizing electromyographic 
(EMG) responses from submaximal discontinuous work bouts on the bicycle ergometer 
to determine the physical working capacity at the fatigue threshold (PWCFT). The 
subjects for this study included 32 males, 18-29 years old, with fitness levels ranging 
from highly trained to untrained and sedentary. The same IEMG equipment and 
procedures were used in this study as in the previous study conducted by deVries et al. 
(1982). The onset of blood lactate accumulation (OBLA), percent heart rate range 
(%HRR) at the PWCFT, heart rate- workload (HR-WL) relation, critical power (CP) and 
ratings of perceived exertion (RPE) at the PWCFT were measured for each subject. These 
measurements were used to examine the validity of the PWCFT model through 
correlational and regression analyses. The procedures for measuring the PWCFT included 
multiple discontinuous work bouts on the bicycle ergometer at increasing intensities, with 
the measurement of IEMG amplitude. The subject’s heart rate returned to within 10 
b·min-1  of the resting value before the next work bout was initiated. The first work bout 
was performed at 420 kpm·min-1 and increased by 420 kpm·min-1 for each subsequent 
work bout (3 total). The PWCFT was determined as the average of the highest power 
output with no change in IEMG amplitude over time and the lowest power output that 
resulted in an increase in IEMG amplitude.  Seventeen of the subjects were retested on a 
different day to determine the reliability of the PWCFT test. The authors found that PWCFT 
was highly reproducible, with a test-retest correlation of r= 0.947 and a SEE of 145.6 
kpm·min-1 (9.7% of the mean PWCFT). The results also showed the OBLA, % HRR, and 
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HR-WL relationship accounted for 70% of the total variance in the PWCFT. In 
conclusion, the PWCFT model was shown to be valid and highly reproducible, providing 
an attractive alternative to supramaximal tests for untrained or sedentary individuals. 
deVries et al. (1990) 
The purpose of this study was to examine alternative methodological procedures 
for the determination of the physical working capacity at the fatigue threshold (PWCFT) 
to improve the practical application and extend the utility of the test. This study examined 
the use of a continuous test protocol rather than a discontinuous protocol. In addition, the 
PWCFT estimates were compared for treadmill and bicycle ergometer exercise, from a 
bipolar electromyographic (EMG) lead system and a unipolar lead system, as well as the 
potential for residual fatigue from tests repeated 24 hours apart. Twenty subjects 
participated in this study, with a wide age (19-70 years) range and different fitness levels. 
Each subject participated in one or more of the experiments conducted. For each 
experiment EMG data and fatigue curves were recorded as previously described by 
deVries et al. (1987). The initial power output was set based on the subject’s estimate of 
their fitness level and abilities and was then incrementally increased by 12-25 W at each 
stage for the bicycle ergometer tests and by one to two percent grade increases for the 
treadmill test. The first experiment was a comparison continuous versus discontinuous 
protocol on the bicycle ergometer. For the discontinuous test, the subjects rested until 
their HR was within 10 b·min-1 of their resting value between each power output or grade 
increase. The continuous test followed the same procedures as the discontinuous test 
except for there was no rest interval between each increase in intensity. The PWCFT was 
determined as the average of the highest power output with no change in IEMG 
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amplitude over time and the lowest power output that resulted in an increase in IEMG 
amplitude. There was no mean difference between the PWCFT estimates from the 
discontinuous versus continuous test on the bicycle ergometer and they were highly 
correlated (r=0.856). The PWCFT estimates from the treadmill versus bicycle ergometer 
involved 6 of the 20 subjects, for both the continuous and discontinuous protocols. Since 
there is no direct measurement of work or power for exercise on a treadmill, to determine 
PWCFT the highest heart rates (HR) achieved during the two-minute period in which the 
fatigue threshold was reached (i.e., increase in EMG amplitude) were compared from the 
bicycle ergometer test and treadmill test. The EMG data were collected from the 
quadriceps and gastrocnemius muscles for the treadmill test. The results showed that 
there was no significant difference between the mean HR at the PWCFT between the two 
different muscle groups, however, the HR at the PWCFT was 20-35 b·min-1  lower on the 
bicycle ergometer compared to the treadmill. The unipolar versus bipolar lead systems 
test showed that the mean voltages from the unipolar measurements were significantly 
greater than for the bipolar, but they were well correlated (r=0.841). The PWCFT 
estimates from unipolar and bipolar were not significantly different (t= 1.09 p>0.05). 
Furthermore, the effect of 24-hour repeated tests showed that there was no residual 
fatigue effect for discontinuous PWCFT tests repeated at a 24 hour interval.  
Summary 
The Physical Working Capacity at the Fatigue Threshold Model (PWCFT) was 
developed by deVries et al. (1982) to examine the onset of neuromuscular fatigue. This 
model utilized surface electromyography (EMG) from the quadriceps muscle. The 
amplitude (AMP) of the EMG signal was plotted versus time for a series of constant 
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work rate rides. The PWCFT was defined as the highest constant power output that could 
be maintained during cycle ergometry without an increase in EMG AMP. deVries et al. 
expanded upon the initial study, and in 1990 an experiment to determine factors that may 
affect the estimation of the PWCFT. Overall, it was concluded that the model could be 
extended to treadmill running, conducted using bipolar or unipolar leads, but most 
importantly, that a continuous exercise protocol could be implemented instead of the 
previously utilized, discontinuous protocol.  
2.5 Utilization of PWCFT to Examine the Efficacy of Nutritional Supplements to 
Improve Performance 
Camic et al (2010a) 
The purpose of this study was to examine the effects of 4 weeks of arginine-based 
supplementation on the physical working capacity on the fatigue threshold (PWCFT). 
Arginine serves as a precursor in the production of nitric oxide (NO) and plays an 
important role in endothelium-dependent vasodilation. Due to these physiological effects, 
arginine supplementation may help to increase blood flow to the myocardium and 
skeletal muscle. This was a double-blind, placebo-controlled, parallel design which 
included 50 college aged men who were randomly placed into one of three groups: 1) 
placebo, 2) 1.5 g arginine or 3) 3.0 g arginine. All of the subjects performed a pre-
supplementation (PRE) incremental test to exhaustion on a cycle ergometer to determine 
the PWCFT and performed the exact same protocol after 4 weeks of arginine 
supplementation. The subjects were instructed to take one dose (4 pills) of their assigned 
supplement on an empty stomach immediately after they woke up every morning with 16 
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oz. of water for 28 days. The subjects were instructed not to change their dietary or 
exercise habits during the supplementation period. At their post supplementation (POST) 
visit subjects took one dose 60 minutes prior to the test. The incremental test to 
exhaustion protocol has previously been described by deVries et. al. (1987) Surface EMG 
signals were recorded from the vastus lateralis using a bipolar electrode arrangement 
during the incremental tests for the determination of the PRE and POST supplementation 
PWCFT values. The results of the study indicated significant increases in the PWCFT 
values for the 1.5 g (22.4%) and 3.0 g (18.8%) supplement groups, but no change for the 
placebo group (-1.6%). These findings were likely due to the physiologic actions of 
arginine combined with grape seed extract, which help reduce the concentrations of 
metabolic by-products produced during exercise, improved blood flow associated with 
increased NO synthesis and decreased endothelin production. In conclusion, arginine 
based supplements can be used as an ergogenic aid for untrained individuals to increase 
time to fatigue and potentially improve exercise performance.  
Summary 
Arginine has been shown to serve as a precursor in the production of nitric oxide 
(NO) and plays an important role in endothelium-dependent vasodilation (Camic et al. 
2010a). Due to these physiological effects, arginine supplementation may help to increase 
blood flow to the myocardium and skeletal muscle and may have an affect on the PWCFT. 
Camic et al. (2010a) conducted a study in which examined the effects 28 days of 
supplementation with a placebo, 1.5g arginine, and 3.0g arginine on the PWCFT. The 
results of the study (Camic et al. 2010a) indicated significant increases in the PWCFT for 
the 1.5 g (22.4%) and 3.0 g (18.8%) supplement groups, but no change for the placebo 
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group (-1.6%). These findings were likely due to the physiologic actions of arginine 
combined with grape seed extract, which help reduce the concentrations of metabolic by-
products produced during exercise, improved blood flow associated with increased NO 
synthesis, and decreased endothelin production. In conclusion, supplementation with a 
compound (arginine) that improves endothelial function and blood flow can be used as an 
ergogenic aid for untrained individuals to increase time to fatigue and potentially improve 
exercise performance.  
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CHAPTER 3. METHODS 
3.1 Experimental Design and Supplementation  
The present study used a randomized, double-blind, placebo- controlled, parallel design. 
For this study, there were three groups, two experimental groups and one control. Due to 
the low bioavailability of curcumin, it was taken in combination with galactomannan 
soluble dietary fiber from fenugreek seeds in a supplement called CurQfen®, which has 
been shown to significantly increase plasma concentrations of curcumin (Krishnakumar 
et al. 2012). The first visit to the laboratory was to determine each subject’s PWCFT-PRE, 
?̇?O2 peak-PRE, and Tlim-PRE from graded exercise test to exhaustion (GXT) on an 
electronically braked ergometer. Following the PRE-test, 47 subjects were randomly 
assigned to either the control group (placebo: PLA, n=15), CurQfen® (CUR, n=18), or 
fenugreek soluble fiber (FEN) (n=14) and were given instructions regarding the 
supplementation process. The supplements were taken daily for 28 days, in the morning 
before eating, with 16 oz. of water. The CurQfen® dosage was 500 mg with 100 g of 
CurQfen® powder that contained 37 to 38 g of natural curcuminoids (including curcumin 
(31g), demethoxy curcumin (6g) and bisdemethoxy curcumin (1.1g)) along with 60 g of 
de-bitterised fenugreek dietary fiber rich in galactomannans, and a 2 to 4% moisture 
content. The fenugreek only group was included to account for any extraneous effects of 
fenugreek soluble fiber and contained 300mg.  During the supplementation period, the 
subjects were instructed not to change their dietary habits or increase their activity level. 
Food logs were kept for three days prior to the PRE- and POST-test to determine the total 
grams consumed for each macronutrient as well as total kilocalories. In total, 41 of the 47 
subjects completed and returned the food logs for PRE- and POST-test and were included 
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in the subsequent analyses of total kilocalories and grams of macronutrients consumed. 
The subjects checked in every week to ensure adherence to the protocol and compliance 
to the supplementation regimen. To be included in the final analyses, subjects had to 
demonstrate > 80% compliance (compliance = [# of capsules consumed / # of capsules 
provided] x 100). After 28 days of supplementation, the subjects returned to the 
laboratory for their POST-test to determine PWCFT-POST, ?̇?O2 peak-POST, and Tlim-
POST. 
3.2 Subjects  
The subjects recruited for the present investigation were college-aged, aerobically 
untrained individuals. The subjects were not highly trained, specifically in bicycling, and 
participated in no more than 3 days a week of regular activity (<4 hours per week). In 
total, 67 subjects were recruited to participate in this study, and 47 were included in the 
final analyses. Of the initial 67 subjects, three subjects withdrew from the study due to 
scheduling conflicts, one withdrew due to illness, and five were excluded due to 
equipment malfunctions. From the remaining 58 subjects, two were excluded due to an 
inability to complete minimal stage requirements for the GXT, and nine subjects did not 
have a detectable PWCFT at either the PRE- or POST-test. All of the 47 subjects included 
in the final analyses were > 80% complaint (mean ± SD: 27.88 ± 0.51). All of the 
subjects completed a health history questionnaire and met the following criteria: (a) no 
history of medical or surgical events that could significantly affect experimental results or 
increase the subjects risk of injury, these included cardiovascular disease, metabolic, 
renal, hepatic, or musculoskeletal disorders; (b) were not taking any medication that 
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could significantly affect experimental results; (c) not currently using any nutritional 
supplements that could significantly affect experimental results; and (d) not presently 
participating in another clinical trial or ingestion of another investigational product. The 
study was approved by the University’s Institutional Review Board for Human Subjects, 
and all subjects were given a health screening and signed a written informed consent 
document before testing. 
3.3 Determination of V̇O2 peak 
Each subject performed a GXT to exhaustion on a calibrated electronically-braked cycle 
ergometer (Lode Corival, Groningen, The Netherlands) to determine the PWCFT, V̇O2 
peak, and Tlim at PRE- and POST-test. The ergometer seat height was adjusted so that the 
subject’s legs reach near full extension at the bottom of the pedal revolution. Toe clips 
were used to maintain pedal contact throughout the test and all subjects were equipped 
with a nose clip and a 2-way valve mouth piece to collect all expired air. Expired gas 
samples were collected and analyzed using a calibrated metabolic cart (TrueMax 2400, 
ParvoMedics, Sandy, UT). The gas analyzers were calibrated with room air and gases of 
known concentration prior to all testing sessions. In addition, subjects wore a Polar Heart 
Rate Monitor (Polar Electro Inc., Lake Success, NY), synchronized with the metabolic 
cart to obtain heart rate measures throughout the ride. The test began at 50 W at a 
cadence of 70 rev·min-1 and the power output increased by 30 W every 2 min until 
voluntary exhaustion or the subject’s pedal rate dropped below 70 rev·min-1 for more than 
10 seconds, despite strong verbal encouragement. The V̇O2 peak was defined as the 
highest V̇O2 value in the last 30 seconds of the test that met two of the following three 
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criteria: 1) 90% of age-predicted heart rate; 2) respiratory exchange rate > 1.1; and 3) a 
plateau of oxygen uptake (less than 150 mL·minˉ¹ in V̇O2  over the last 30 seconds of the 
test).  
3.4 Electromyographic Measurements 
The EMG signals were measured from the vastus lateralis (VL) on the dominant 
leg during the incremental test. Prior to electrode placement, the skin at each site was 
shaved, carefully abraded, and cleaned with alcohol. A bipolar surface electrode (circular 
24 mm, Kendall disposable EMG electrodes, Covidien LTD; Gosport Hampshire, UK) 
arrangement (2.0 cm center-to-center) was placed based on the recommendations from 
the SENIAM Project for EMG electrodes placement (Hermans et al. 1999). Specifically, 
a reference line was drawn over the VL, one-third of the distance between the lateral 
superior border of the patella and the anterior superior iliac spine. In addition, the 
electrode-placement site was located 5 cm lateral to the reference line so that the 
electrodes were over the VL muscle (Malek et al. 2006). A goniometer (Smith & Nephew 
Rolyan, Inc., Menomonee Falls, WI) was used to orient the EMG electrodes at a 20° 
angle to the reference line to approximate the pennation angle of the muscle fibers for the 
VL (Abe et al. 2000). The EMG signal was amplified (gain: ×1,000) using differential 
amplifiers (EMG 150 BIOPAC Systems, Inc., Santa Barbra, CA, bandwidth = 10– 500 
Hz).  
3.4.1 Signal Processing 
The raw EMG signals were digitized at 1,000 Hz, stored in a personal computer 
(MacBook Pro OSX, version 10.6.8, Apple Inc., Cuperino, CA) for subsequent analysis 
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and processed with a custom program written with LabVIEW programming software 
(version 7.1, National Instruments, Austin, TX). The EMG signals will be bandpass-
filtered (zero phase shift, fourth-order Butterworth) at 10-500 Hz. Continuous 10 s 
epochs for the EMG AMP (microvolts root mean square, μVrms) and EMG MPF (MPF 
in Hz) were calculated. For the MPF analyses, each data segment was processed with a 
Hamming window and a discrete Fourier transform (DFT) algorithm in accordance with 
the recommendations of Hermens et al. (1999). The MPF were selected to represent the 
power spectrum on the basis of the recommendations of Hermans et al. (1999) and was 
calculated as described by Kwatny et al. (1970). 
3.5 Determination of the Physical Working Capacity at the Fatigue Threshold 
(PWCFT) 
The protocol used to determine the PWCFT has previously been described in detail by 
deVries et al. (1987) and was conducted simultaneously with the GXT. Briefly, the test 
began at a power output of 50 W, and was increased by 30 W every 2 min until voluntary 
exhaustion or the subject could no longer maintain a pedal cadence of 70 rpm. During 
each 2-minute power output, 12, 10-second EMG samples were recorded from the VL 
muscle. The EMG amplitude values for each of the 12, 10-second periods were plotted 
across time for each power output of the test. The PWCFT was defined as the average of 
the highest power output that results in a non-significant slope coefficient and the lowest 
power output that results in a significant positive slope coefficient.   
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3.6 Statistical Analyses 
Separate, one-way ANOVAs were used to determine if there were any significant 
differences among the PLA, FEN, and CUR groups for age, height, weight, PWCFT, V̇O2
peak, and Tlim, at PRE-test. The test-retest reliability (PRE- and POST-test values) for 
each dependent variable was determined using the ICC2,1 model (Weir, 2005) for the 15 
subjects in the PLA group. The standard error of the measurement (SEM = SD√1 − 𝐼𝐶𝐶) 
and minimal difference need to be considered real (MD) (MD =𝑆𝐸𝑀 𝑥 1.96 𝑥 √2 ) were 
also calculated for the PLA group for each dependent variable. In addition, three separate 
paired samples t-test were used to determine if there were any significant changes in the 
PWCFT, ?̇?O2 peak, or Tlim from PRE- to POST-test for the PLA. Three separate, one-way 
ANCOVAs were used to examine differences among group for each dependent variable, 
PWCFT, ?̇?O2, and Tlim. The respective PRE-test value was used as the covariate. The total 
caloric (kilocalories) and macronutrient (grams of carbohydrate, fat, and protein) intake 
was analyzed with separate, 3 (Group: CUR, FEN, and PLA) x 2 (Time: PRE and POST) 
mixed-factorial ANOVAs. A significant main effect was followed up with one-way 
ANOVAs and independent samples t-test. An alpha of p ≤ 0.05 was considered 
statistically significant for all comparisons. 
CHAPTER 4. RESULTS 
The results of the one- way ANOVAs comparing pre-test values indicated that there were 
no significant mean group differences for the PWCFT (F= 0.705, p= 0.500), ?̇?O2 (F= 
1.367, p= 0.266), or Tlim (F= 0.988, p= 0.381) determined from the GXT or for age (F= 
1.469 p= 0.241), height (F= 0.050 p= 0.951), or weight (F= 1.62 p= 0.209) values.  
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Table 1. Demographic information and PRE test values for time to exhaustion (Tlim), V̇O2 
peak, and the physical working capacity at the fatigue threshold (PWCFT). 
Variable Placebo (n= 15) Fenugreek (n=14) Curcumin (n= 18) 
Age (years) 20.27 r 1.44 20.86 r 1.56 21.78 r 3.66 
Height (cm) 174.81 r 6.77 175.07 r 7.58 175.62 r 8.09 
Weight (kg) 73.24 r 12.83 79.91 r 12.14 71.90 r 13.89 
Time to exhaustion 
(min) 
13.87 r 2.69 15.13 r 2.53 15.25 r 3.60 
?̇?O2 peak (ml·kg-1·min-
1) 
39.20 r 8.95 37.82 r 6.35 42.32 r 8.22 
PWCFT (W) 153.00 r 54.93 176.43 r 43.12 170.00 r 63.64 
4.1 Reliability Analysis 
The paired samples t-tests indicated that there were no significant mean 
differences between PRE- and POST-test for the PLA group for the PWCFT (t= -0.764 p= 
0.458), ?̇?O2 peak (t= 0.452 p= 0.658), and Tlim (t= -0.137 p= 0.893). The ICC2,1 values for 
the PWCFT, ?̇?O2 peak, and Tlim were 0.834, 0.944, and 0.953, respectively. The SEM and 
MD values for the PWCFT, ?̇?O2peak, and Tlim are presented in Table 2. 
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Table 2. Results of the reliability analyses for the placebo group using PRE- and POST-
test values for the physical working capacity at the fatigue threshold (PWCFT), ?̇?O2 peak, 
and time to exhaustion (Tlim).  
Subject PRE-
PWCFT 
(W) 
POST-
PWCFT
(W) 
PRE- 
?̇?O2 peak 
(L·min-1) 
POST- 
?̇?O2 peak 
(L·min-1) 
PRE-Tlim 
(min) 
POST- Tlim
(min) 
1 95 155* 2.41 2.28 12.52 11.02 
2 275 275 4.07 4.20 19.01 18.76 
3 155 185 3.54 3.24 15.00 15.51 
4 185 125** 3.43 2.72 14.39 13.01 
5 185 155 3.42 3.51 15.50 15.52 
6 155 125 2.47 2.29 12.49 11.52 
7 155 155 2.15 2.08 11.01 11.40 
8 125 125 2.2 2.14 11.50 11.51 
9 215 245 3.61 3.72 17.51 18.40 
10 65 95 2.89 3.13 14.01 15.01 
11 65 95 1.58 1.40 8.51 8.01 
12 125 155 3.01 3.27 15.00 16.50 
13 155 155 2.56 2.61 14.00 13.32 
14 155 155 2.06 2.22 11.51 12.46 
15 185 185 3.31 3.46 16.00 16.51 
Mean 
± SD 
153 ± 
54.93 
159 ± 
49.25 
2.85 ± 
0.708 
2.82 ± 
0.760 
13.87 ± 
2.69 
13.90 ± 
3.02 
ICC 0.834 0.944 0.953 
SEM 21 0.171 0.61 
MD 58 0.474 1.69 
*Indicates that the subject had an increase in the PWCFT that exceeded the minimal 
difference to be considered a real change (MD). ** Indicates that the subject had a
decrease in the PWCFT that exceeded the MD.
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4.2 Mean Group Comparisons 
The one-way ANCOVA for the PWCFT values indicated there were no significant 
differences among groups (F = 3.141, p= 0.053), however pairwise comparisons 
indicated a significant difference between the CUR and PLA groups (p= 0.016), but no 
differences between FEN and CUR (p=0.321) or FEN and PLA (p= 0.171). Therefore, 
separate one-way ANCOVAs were used to examine the adjusted PWCFT means for the 
PLA vs. CUR (F = 4.906, p =0.035) and the PLA vs. FEN (F = 2.969, p = 0.097). The 
adjusted PWCFT mean (rSD) for the CUR (192.88 r 58.41W; 95% CI 175.98W- 
209.77W) was significantly greater (p= 0.035) than the PLA (165.55r 49.25W; 95% CI 
147.02W-184.07W). The adjusted POST PWCFT means (rSD) for the PLA (166.66r 
49.25W; 95% CI 153.14W- 180.18W) and FEN (183.22r 31.53W (95% CI 169.21W- 
197.23W) were not significantly different (p= 0.097) (Figure 1 and 2). The one- way 
ANCOVA for ?̇?O2 peak (F = 0.612, p = 0.612) and Tlim (F = 0.688, p = 0.508) indicated 
there were no significant differences among groups (Figure 3 and 4).  
The 3 x 2 mixed factorial ANOVAs resulted in no significant group x time 
interactions, main effects for group, or main effects for time for total kilocalories, or 
carbohydrates (g) and protein (g). However, there was a significant main effect for group 
for fat (g) (F= 4.327, p= 0.020). A follow up one- way ANOVA (F= 4.327, p= 0.020) and 
between subject t-test indicated that the fat intake (collapsed across time) was greater for 
FEN compared to PLA (p= 0.015) and CUR (p= 0.014), but there was no difference 
between CUR and PLA (p= 0.954). Supplement compliance was recorded with 
supplementation logs and demonstrated a mean (± SD) compliance rate of 99.5% ± 
0.51%. 
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Figure 1. Adjusted POST-test physical working capacity at the fatigue threshold (PWCFT) 
(mean r SEM) values (covaried for PRE PWCFT scores) for the feugreek soluble fiber 
(FEN) and placebo (PLA) groups. 
Figure 2. Adjusted POST-test physical working capacity at the fatigue threshold (PWCFT) 
(mean r SEM) values (covaried for PRE PWCFT scores) for the curcumin+fenugreek 
soluble fiber (CUR) and placebo (PLA) groups. 
*Significantly (p< 0.05) greater than placebo.
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Figure 3. Adjusted POST-test peak oxygen consumption (?̇?O2 peak) (mean r SEM) 
values (covaried for PRE ?̇?O2 scores) for the curcumin+fenugreek soluble fiber (CUR), 
fenugreek soluble fiber (FEN), and placebo (PLA) groups. 
Figure 4. Adjusted POST-test time to exhaustion (Tlim) (mean r SEM) values (covaried 
for PRE Tlim scores) for curcumin+fenugreek soluble fiber (CUR), fenugreek soluble 
fiber (FEN), and placebo (PLA) groups.  
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4.3 Individual Responses  
Four of the 18 subjects in the CUR group (Figure 5), one of the 14 subjects in the FEN 
group (Figure 6), and one of the 15 subjects in the PLA group (Figure 7) had a value 
greater than the minimal difference for the PWCFT, but none of the subjects in the PLA, 
FEN, or CUR groups exceeded the MD for ?̇?O2 peak or Tlim (Figures 8-13).  
Figure 5. Individual responses for the physical working capacity at the fatigue threshold 
(PWCFT) from PRE- to POST-test for the curcumin+fenugreek soluble fiber (CUR) 
supplement group. Solid line indicates the subject had an increase greater than the 
minimal difference (MD=60W). Dashed line (---) = no change, dashed and dotted line (- . 
-) = decrease, and dotted line (…) = increase, not greater than the MD. Note there were 4 
subjects who had increases greater than MD, two solid subject lines overlap at 155- 
245W.  
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Figure 6. Individual responses for the physical working capacity at the fatigue threshold 
(PWCFT) from PRE- to POST-test for the fenugreek soluble fiber (FEN) supplement 
group. Solid line indicates the subject had an increase greater than the minimal 
difference. Dashed line (---) = no change, dashed and dotted line (- . -) = decrease, and 
dotted line (…) = increase, not greater than the MD. 
Figure 7. Individual responses for the physical working capacity at the fatigue threshold 
(PWCFT) from PRE- to POST-test for the placebo (PLA) supplement group. Solid line 
indicates the subject had an increase greater than the minimal difference, dashed, double 
dot, dashed (- . . -) line indicates the subject had a decrease greater than the minimal 
difference. Dashed line (---) = no change, dashed and dotted line (- . -) = decrease, and 
dotted line (…) = increase, not greater than the MD. 
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Figure 8. Individual responses for ?̇?O2 peak from PRE- to POST-test for the 
curcumin+fenugreek soluble fiber (CUR) supplement group. Solid line indicates the 
subject had an increase greater than the minimal difference, dashed, double dot, dashed 
(- . . -) line indicates the subject had a decrease greater than the minimal difference. 
Dashed line (---) = no change, dashed and dotted line (- . -) = decrease, and dotted line 
(…) = increase.  
Figure 9. Individual responses for ?̇?O2  peak from PRE- to POST-test for the fenugreek 
soluble fiber (FEN) supplement group. Solid line indicates the subject had an increase 
greater than the minimal difference, dashed, double dot, dashed (- . . -) line indicates the 
subject had a decrease greater than the minimal difference. Dashed line (---) = no change, 
dashed and dotted line (- . -) = decrease, and dotted line (…) = increase.  
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Figure 10. Individual responses for ?̇?O2  peak from PRE- to POST-test for the placebo 
(PLA) supplement group. Solid line indicates the subject had an increase greater than the 
minimal difference, dashed, double dot, dashed (- . . -) line indicates the subject had a 
decrease greater than the minimal difference. Dashed line (---) = no change, dashed and 
dotted line (- . -) = decrease, and dotted line (…) = increase.  
Figure 11. Individual responses for time to exhaustion from PRE- to POST-test for the 
curcumin+fenugreek soluble fiber (CUR) supplement group. Solid line indicates the 
subject had an increase greater than the minimal difference, dashed, double dot, dashed (- 
. . -) line indicates the subject had a decrease greater than the minimal difference. Dashed 
line (---) = no change, dashed and dotted line (- . -) = decrease, and dotted line (…) = 
increase.  
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Figure 12. Individual responses for time to exhaustion from PRE- to POST-test for the 
fenugreek soluble fiber (FEN) supplement group. Solid line indicates the subject had an 
increase greater than the minimal difference, dashed, double dot, dashed (- . . -) line 
indicates the subject had a decrease greater than the minimal difference. Dashed line (---) 
= no change, dashed and dotted line (- . -) = decrease, and dotted line (…) = increase.  
Figure 13. Individual responses for time to exhaustion from PRE- to POST-test for the 
placebo (PLA) supplement group. Solid line indicates the subject had an increase greater 
than the minimal difference, dashed, double dot, dashed (- . . -) line indicates the subject 
had a decrease greater than the minimal difference. Dashed line (---) = no change, dashed 
and dotted line (- . -) = decrease, and dotted line (…) = increase.  
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CHAPTER 5. DISCUSSION 
The primary findings of the current study were that 28 days of curcumin+fenugreek 
soluble fiber (CUR) and fenugreek soluble fiber (FEN) supplementation did not affect 
V̇O2peak or Tlim, but the PWCFT was greater at POST-test for the CUR, compared to the 
PLA group. In addition, there was no difference in the PWCFT at POST-test between 
CUR and FEN. The PWCFT increased PRE- to POST-test by 16.7% in the CUR group, 
8.5% in the FEN group, and only by 3.9% in the PLA group. The increase in the PWCFT 
for the CUR group in this study were consistent with the 22.4% and 18.8% increases in 
the PWCFT from PRE- to POST-test previously reported (Camic et al. 2010) after 4 
weeks of daily oral administration of arginine-based supplements (Camic et al. 2010). 
Like arginine, one of the potential physiological actions of curcumin is its role as a 
precursor to nitric oxide (NO) production, which plays an important role in endothelium-
dependent vasodilation (Boonla et al. 2014). Thus, the changes in the PWCFT in the CUR 
supplementation group in the present study were consistent with the changes previously 
reported following 28 days of a nutritional supplement intervention without exercise 
training, and may be related to increased blood flow and metabolic byproduct clearance, 
triggered by increased NO bioavailability, a potent vasodilator (Camic et al 2010).  
The changes observed for the PWCFT for the CUR group in this study were likely 
related to the factors that underlie neuromuscular fatigue and the detection of the 
threshold. The PWCFT is an electromyographic (EMG) technique that theoretically 
estimates the highest power output that can be maintained for an extended period of time 
without evidence of neuromuscular fatigue. Previous studies have examined the potential 
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mechanisms underlying neuromuscular fatigue, which are reflected by increases in the 
EMG signal and include additional motor unit recruitment and/or increases in firing rate 
of the initially recruited motor units to maintain exercise at a constant power output 
(Camic et al 2010, Zuniga et al). For example, it has been suggested (Camic et al 2010, 
Zuniga et al 2010, Bergstrom et al 2013) that the fatigue-induced changes in EMG 
amplitude may be related to the accumulation of various metabolic byproducts and/or 
ions (i.e., inorganic phosphate, hydrogen ions, ammonia and potassium). Further studies 
have shown that the accumulation of these metabolites and ions result in fatigue- induced 
decreases in membrane excitability (Clausen 2013, Enoka and Stuart 1992), excitation-
contraction coupling involving Ca ++ release and uptake from the sarcoplasmic 
reticulum, myofibrillar Ca ++ sensitivity for binding with troponin, actin and myosin 
binding, and ATP production and breakdown (Gladden 2004, MacLaren et al 1989, 
Robergs et al 2004, Westerblad et al 2002). Other studies attribute the recruitment of 
additional motor units to maintain force or power output during a fatiguing task to the 
decrease in intracellular pH as a result of non-mitochondrial ATP hydrolysis, which 
contributes to the decline in muscle fiber conduction velocity (Lindstrom et al 1970, 
Moritani et al 1982). It has been hypothesized (Camic et al 2010) that, during 
incremental cycle ergometry, intracellular [H+] may rise to a critical level, decreasing 
intracellular pH, and interfering with excitation–contraction coupling. These effects 
may result in fatigue changes in induced motor unit activation and an increase in EMG 
amplitude observed at the PWCFT. 
The physiological mechanisms responsible for the ergogenic effects of curcumin 
have not been fully identified, but some reported effects include increased metabolic 
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byproduct clearance (Sahin et al 2016, Huang et al 2015), potentially linked to increased 
NO bioavailability and the subsequent vasodilatory response (Boonla et al 2014), as well 
as increased blood antioxidant capacity, and reduced oxidative stress during exercise 
from decreased levels of reactive oxygen species (ROS) (Takahashi et al 2013). 
Curcumin is an active ingredient of polyphenolic curcuminoids, which can be found in 
the spice turmeric and has been well studied in clinical investigations over the last few 
decades (Boonla et al 2014). It is possible the purported (Boonla et al 2014, Sahin et al 
2016, Takahashi et al 2013) effects of curcumin supplementation to increase clearance of 
metabolic byproducts through improved endothelial function, increased neuromuscular 
time to fatigue and the PWCFT in this study. For example, curcumin has been shown to 
decease the accumulation of metabolic byproducts such as lactate and ammonia (Sahin et 
al 2016), metabolites that have previously been linked to neuromuscular fatigue as they 
accumulate during repeated muscle contractions (Camic et al 2010, Zuniga et al 2010, 
Bergstrom et al 2013). Thus, it is possible curcumin improves clearance of metabolic 
byproducts in the muscle cells through NO mediated vasodilation may increase the time 
to neuromuscular fatigue, and allow the working muscle to perform at a higher power 
output without the changes in muscle activation, thus delaying the PWCFT.
In the present study, fenugreek soluble fiber was added to increase the 
bioavailability of curcumin (Krishnakumar et al 2012), but it may also have physiological 
effects. Fenugreek is a naturally growing plant, originating in India and Northern Africa 
(Srichamroen et al 2008). The seeds and leaves have been used for hundreds of years in 
Ayurvedic and Chinese medicine, however recently, preliminary animal and human trials 
suggest that oral fenugreek seed powder may have possible hypoglycemic and 
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antihyperlipidemic properties (Basch et al 2003). In the present study, the galactomannan 
component of fenugreek was used in the CUR supplement to increase absorption from 
the small intestine (Krishnakumar et al 2012). Galactomannan is a soluble fiber guar 
gum, and a potential active component of fenugreek seeds (Srichamroen et al 2008). 
Specifically, galactomannans from fenugreek have been shown to have effects on 
glycemic and lipidemic status in rats (Srichamroen et al 2008). Specifically, 
galactomannan- fed rats demonstrated significantly less adipose tissue compared to the 
control, suggestive of a high metabolic rate in the tissue that were also associated with 
increased release of FFA into the circulation and decreased plasma insulin levels 
(Srichamroen et al 2008). The authors suggested that the reduction of plasma insulin level 
in galactomannan-fed rats may increase lipolysis in adipose tissue, and consequently 
increase plasma FFA levels and reduce adipocyte size (Srichamroen et al 2008). Thus, it 
is possible the fenugreek component in the CUR and FEN groups increased FFA release 
and decreased insulin levels. These factors may have contributed to the increased 
neuromuscular time to fatigue for the CUR group by delaying the reliance on anaerobic 
energy production and accumulation of metabolic byproducts from glucose metabolism. 
This may also explain, in part, the non-significant difference between the CUR and FEN 
group at POST-test.   
In this study, it appears the purported effects of curcumin to increase NO 
production and aid in metabolic byproduct clearance were effective to increase the 
submaximal neuromuscular fatigue threshold (PWCFT), but did not affect indices of 
maximal performance such as Tlim and V̇O2peak. It is possible the intensity specific 
effects were related to the factors affecting V̇O2peak and the mode of exercise to 
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determine Tlim. Previous investigators (Sahin et al. 2016) have reported decreased levels 
of lactate, ammonia, and muscle malondialdehyde in conjunction with increased run 
times to exhaustion in rodents supplemented with curcumin compared to a placebo. 
Consistent with the findings by Sahin et al. (2016), Huang et al. (2015) reported that 
curcumin supplementation dose-dependently increased grip strength and endurance 
performance and increased muscular glycogen content and reduced levels of physical 
fatigue-associated biomarkers serum lactate, ammonia, and blood urea nitrogen compared 
to the vehicle treatment (Huang et al 2015). Each of these previous endurance tests in 
animal models used submaximal protocols to examine changes in Tlim (Sahin et al 2016, 
Huang et al 2015). In the present study, however, a maximal GXT on a bicycle ergometer 
was utilized, which may not have been sensitive to the physiological changes induced by 
curcumin, due to the observed non-significant increases in time PRE to POST. 
Specifically, although improved metabolic byproduct clearance may have delayed 
neuromuscular fatigue and the PWCFT, an increase in Tlim for the GXT would likely be 
dependent factors that increased the cellular and blood buffering capacities as well as 
improved cellular respiration at maximal intensities. Thus, the results of the present study 
indicated curcumin and fenugreek soluble fiber were effective to delay neuromuscular 
fatigue but did not increase Tlim during a GXT. Future studies should explore the effects 
of curcumin on the sustainability of submaximal exercise performed at or below the 
PWCFT to determine if the factors that improved the threshold might also increase Tlim. 
Similar to Tlim, there were no effects of supplementation on V̇O2 peak in the 
present study. Maximal oxygen uptake (V̇O2 peak) is primarily limited by the ability of 
the cardiorespiratory system to deliver oxygen to the exercising muscles (Basset et al 
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2000), but is also dependent on peripheral factors related to skeletal muscle O2 extraction 
such as capillary and mitochondrial density (Basset et al 2000), which play a critical role 
in improving submaximal endurance performance. Of the many factors which may 
increase michondrial biogenesis, effects of endurance training have been well studied and 
shown to cause an increase in mitochondrial enzyme activities, which improves 
performance by enhancing fat oxidation and decreasing lactic acid accumulation at a 
given V̇O2 (Zamora et al 1995). A study by Zamora et al (1995) found that following 10 
weeks of endurance training in men there was a significant increase in the number of 
mitochondria per area and in the relative surface occupied by the total mitochondria 
profile area. In the present study, it appears 28 days of curcumin supplementation was not 
effective to alter physiological mechanisms which would lead to increases in V̇O2 peak, 
however previous research has demonstrated cellular effects of curcumin 
supplementation in mice that were amplified with exercise (Hamidie et al 2015). 
Specifically, the combination of curcumin supplementation and endurance training has 
the potential to accelerate mitochondrial biogenesis in skeletal muscle by increasing 
cAMP levels (Hamidie et al 2015). In the present study, subjects were only supplemented 
with CUR for 28 days, during which time they were instructed not to change dietary or 
exercise habits. Without an increase in endurance training during supplementation time, it 
is possible that CUR supplementation alone did not have potent enough effects to 
increase cardiac output, which, theoretically, would result in an increase of V̇O2 peak. 
Additionally, according to Basset et al (2000), peripheral cellular changes have been 
shown to improve submaximal performance. Therefore, any potential increases in 
capillary and mitochondrial density as a result from curcumin supplementation may have 
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had an effect on the PWCFT, a submaximal work rate, but not V̇O2 peak, which represents 
maximal exercise. Future studies should aim to investigate whether a longer 
supplementation period, or higher dosages of curcumin may lead to increases in V̇O2
peak. Furthermore, curcumin supplementation with endurance training should be 
investigated, to determine if the combination of the two interventions may lead to an 
increase in V̇O2 peak. 
In the present study, a reliability analysis was used observe individual responses 
and establish the MD, to determine the magnitude of change in PRE- to POST-test values 
necessary to be considered real (Weir 2005). The MD speaks to the sensitivity of the test 
in distinguishing a “real” change from variation or error in measurement (Weir 2005). 
The MD for the change to be real for the PWCFT was 60 W in this study, which reflected 
a delay in neuromuscular fatigue by two stages from PRE to POST-test. In the PLA 
group, one of the 15 subjects had a change greater than the MD, and one subject had a 
change that was less than the MD (~7% of the subjects). In the FEN group, one of the 14 
subjects exceeded the MD (7% of the subjects), and four out of the 18 exceeded the MD 
(22% of the subjects) in the CUR group. Thus, in general the individual subject responses 
in the CUR group were not necessarily reflective of the mean response for the CUR 
group. Therefore, the mean difference at POST-test for the CUR was likely driven by a 
few high responders (exceeded the MD) and more moderate changes for the remaining 
subjects (Figures 5-13). Extended to a larger population, 4-weeks of supplementation 
with curcumin may only be effective for ~20% of individuals. It is possible that the 
subjects who showed improvement in this study had more potential for change, which 
predisposed them to be more sensitive to actions of curcumin supplementation. Factors 
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that may impact an individual’s ability to respond to supplementation include prior 
training status, health history, and potential genetic factors (Roberts et al 2018). Of these 
genetic factors, Bamman et al. (2007) reported that different skeletal muscle biomarkers 
exist between high responders, who showed a marked increase in muscle fiber cross-
sectional area (fCSA), relative to low responders following 16 weeks of resistance 
training. A proposed mechanism for this difference in high versus low responders is the 
difference in levels of skeletal muscle insulin- like growth factor-1 (IGF-1) mRNA 
variants as well as an mRNA indicative of satellite cell differentiation (myogenin). These 
markers were expressed higher in the high responders relative to low responders 
following training (Bamman et al 2007). To date, there is limited evidence whether there 
are high responders versus low responders to nutritional supplements, and the underlying 
mechanisms. Future studies should aim to investigate factors affecting a subject’s 
response to nutritional supplementation. Although the subjects in this study reported 
training frequencies and volume consistent with moderately trained, college aged 
individuals, there was a wide range of cardiorespiratory fitness levels (very poor to 
superior) based on V̇O2peak values measured from the GXT (ACSM’s Guidelines for 
Exercise Testing and Prescription). In addition, subjects were eliminated from 
participation if they had a history of cardiovascular or respiratory illnesses, however, no 
additional measures of health status were taken beyond resting heart rate and blood 
pressure.  Previous investigators have observed the effects of curcumin on arterial 
stiffness in mice due to aging and concluded that curcumin supplementation improves 
large elastic arterial stiffening as a result of aging, NO-mediated vascular endothelial 
dysfunction, decreases oxidative stress and increases collagen and advanced glycation 
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end products (AGEs) in mice (Fleenor et al 2013). It is possible that the subjects who 
demonstrated significant improvements after supplementation were more sensitive to 
change due to factors like arterial stiffness. Future studies should examine cardiovascular 
health measures and prior training status to determine if these factors are related to the 
potential for an individual to respond to curcumin supplementation. 
Potential limitations of this study may be the result of the inability of to 
consistently monitor subject’s actives and habits over the duration of the study. To ensure 
compliance, subjects were given only 7 days of the supplement at a time, along with a 
dosing log and were required to check in with investigators weekly to report if they had 
missed any doses before receiving their next supply. Subjects were only included in the 
study if they were 80% compliant with their supplementation (compliancy = (# of doses 
consumed / total # of doses provided) x 100), however, there was no measure included to 
determine levels of curcumin in the circulation. Furthermore, to rule out the potential 
effects of exercise or nutrition on the results, the subjects kept an exercise log over the 28 
days as well as a food log for the three days leading up to the PRE-and POST tests and 
were instructed not to change dietary or exercise habits. Lastly, other factors that may 
affect performance, such as sleep, and study habits were not measured and quantified, 
which could have an effect if changed or disrupted over the course of the study.  
In conclusion, CurQfen® supplementation increased the PWCFT compared to a 
placebo, but not compared to fenugreek alone. However, there were no effects of 
CurQfen® on V̇O2 peak or Tlim. The mechanisms responsible for delaying time to 
neuromuscular fatigue may include increased NO production, and increased blood flow 
to remove metabolic byproducts. Considering individual responses, CurQfen® 
46 
supplementation resulted in a real change in the PWCFT for a small portion of the subjects 
(~20%). These findings suggested that CurQfen® supplementation without exercise 
training may help to improve time to neuromuscular fatigue in certain individuals, but the 
group mean analyses were not necessarily reflective of the responses for a majority of the 
subjects.  
47 
REFERENCES 
Abe T, Kumagai K, Brechue WF (2000) Fascicle length of leg muscle is greater in 
sprinters than distance runners. Med Sci Sport Exerc 32:1125-1129 
Bamman, M M., Petrella, J K., Kim, J S., Mayhew, D L., and Cross, J M. (2007). Cluster 
analysis tests the importance of myogenic gene expression during myofiber hypertrophy 
in humans. J. Appl. Physiol. 102, 2232–2239 
Basch E, Ulbricht C, Kuo G, Szapary P, Smith M (2003). Therapeutic Applications of 
Fenugreek. Alternative Medicine Review. Volume 8, Number 1: 20-27 
Basset D R Jr., Howley E T (2000). Limiting factors for maximum oxygen uptake and 
determinants of endurance performance. Med Sci Sports Exerc. 32(1):70-84 
Bergstrom H C, Housh T J, Cochrane K C, Jenkins N D M1, Lewis R W Jr, Traylor D A, 
Zuniga J M 2, Schmidt J R, Johnson G O, Cramer J T (2013) An examination of 
neuromuscular and metabolic fatigue thresholds. Physiol. Meas. 34 (2013) 1253–1267 
Boonla O, Kukongviriyapan U, Pakdeechote P, Kukongviriyapan V, Pannangpetch P, 
Prachaney P, Greenwald E S (2014). Curcumin improves endothelial dysfunction and 
vascular remodeling in 2K-1C hypertensive rats by raising nitric oxide availability and 
reducing oxidative stress.  
48 
Camic L C, Housh T J, Johnson G O, Hendrix C R, Zuniga J M, Mielke M and Schmidt 
R J (2010a). An EMG frequency-based test for estimating the neuromuscular fatigue 
threshold during cycle ergometry Eur. J. Appl. Physiol. 108 337–45  
Camic L C, Housh T J, Zuniga J M, Hendrix C R, Mielke M, Johnson G O and Schmidt 
R J (2010b) Effects of arginine based supplements on the physical working capacity at 
the fatigue threshold J. Strength Cond. Res. 24 1306–12  
Clausen T 2013 Excitation- induced exchange of Na + , K + , and Cl − in rat EDL muscle 
in vitro and in vivo: physiology and pathophysiology J. Gen. Physiol. 141 179–92 
Davis J M, Murphy E A, Carmichael M D, Zielinski M R, Groschwitz C M, Brown A 
S, Gangemi J D, Ghaffar A, Mayer E P (2007). Curcumin effects on inflammation and 
performance recovery following eccentric exercise-induced muscle damage. Am J Physiol 
Regul Integr Comp Physiol. 2007 Jun; 292(6): R2168-73 
deVries  H A, Moritani T, Nagata A, Magnussen K (1982). The relation between critical 
power and neuromuscular fatigue as estimated from electromyographic data. The Journal 
of Ergonomics.  
deVries H A, Tichy W M, Housh J T, Smyth D K, Tichy M A, Housh J D (1987). A 
method for estimating physical working capacity at the fatigue threshold (PWCFT). The 
Journal of Ergonomics.  
49 
deVries H A, Housh J T, Johnson O G, Evans A S, Tharp D G, Housh J D, Hughes A R 
(1990). Factors affecting the estimation of physical working capacity at the fatigue 
threshold. The Journal of Ergonomics.  
Enoka R M and Stuart D G (1992). Neurobiology of muscle fatigue J. Appl. Physiol. 72 
1631–48  
Fleenor B S, Sindler A L, Marvi N K, Howell K L, Zigler M L, Yoshizawa M, Seals D R 
(2013). Curcumin Ameliorates Arterial Dysfunction and Oxidative Stress with Aging. 
Exp Gerontol. 48(2):269-76. 
Gladden L B (2004). Lactate metabolism: a new paradigm for the third millennium J. 
Physiol. 558 5–30 
Hamidie R D R, Yamada T, Ishizawa R, Saito Y, Masuda K (2015). Curcumin treatment 
enhances the effect of exercise on mitochondrial biogenesis in skeletal muscle by 
increasing cAMP levels. 
Hermens H J, Freriks B, Merletti R, Stegeman D, Blok J, Rau G, Disselhorst-Klug C, 
Hägg G (1999) Seniam 8: European recommendations for surface electromyography: 
results of the seniam project. Roessingh Research and Development 
Huang W C, Chiu W C, Chuang H L, Tang D W, Lee Z M, Wei L, Chen F A, Huang C 
C (2015). Effect of Curcumin Supplementation on Physiological Fatigue and Physical 
Performance in Mice. Nutrients 2015, 7, 905-921  
50 
Krishnakumar I M, Ravi A, Kumar D, Kuttan R, Maliakel B (2012). An enhanced 
bioavailable formulation of curcumin using fenugreek-derived soluble dietary fibre. 
JOURNAL OF FUNCTIONAL FOODS 4 (2012) 348–357 
Kwatny E D, Thomas D H, Kwanty H G (1970) An application of signal processing 
techniques to the study of myoelectric signals. IEEE Trans Biomed Eng 17:303–313 
Lindstrom L, Magnusson R, Petersen I (1970). Muscular fatigue and action potential 
conduction velocity changes studied with frequency analysis of EMG signals. 
Electromyography 10:341– 356  
MacLaren DP, Gibson H, Parry-Billings M, Edwards RH (1989). A review of metabolic 
and physiological factors in fatigue. Exerc Sport Sci Rev 17:29–66  
Moritani T, Nagata A, Muro M (1982) Electromyographic manifes- tations of muscular 
fatigue. Med Sci Sport Exerc 14:198–202 
Malek M H, Housh T J, Coburn J W, Weir J P, Schmidt R J, Beck T W (2006) The 
effects of interelectrode distance on electromyographic amplitude and mean power 
frequency during incremental cycle ergometry.. J Neurosci Methods 151:139-47 
Robergs R A, Ghiasvand F and Parker D (2004). Biochemistry of exercise-induced 
metabolic acidosis Am. J. Physiol. Regul. Integr. Comp. Physiol. 287 R502–16 
Roberts M D, Haun C T, Mobley C B, Mumford P W, Romero M A, Roberson P A, 
Vann C G, McCarthy J J (2018). Physiological Differences Between Low Versus High 
Skeletal Muscle Hypertrophic Responders to Resistance Exercise Training: Current 
Perspectives and Future Research Directions. Front. Physiol. 2018. 
51 
Sahin K, Pala R, Tuzcu M, Ozdemir O, Orhan C, Sahin N, Juturu V (2016). Curcumin 
prevents muscle damage by regulating NF-kB and Nrf2 pathways and improves 
performance: an in vivo model. J Inflamm Res. 2016; 9: 147–154 
Srichamroen A, Field C J, Thomson A B R, Basu T K (2008). The Modifying Effects of 
Galactomannan from Canadian-Grown Fenugreek (Trigonella foenum-graecum L.) on 
the Glycemic and Lipidemic Status in Rats. J Clin Biochem Nutr. 43(3): 167–174. 
Takahashi M, Suzuki K, Kim H K, Otsuka Y, Imaizumi A, Miyashita A, Sakamoto S 
(2013) Effects of Curcumin Supplementation on Exercise- Induced Oxidative Stress in 
Humans. Int J Sports Med 2014; 35(06): 469-475 
Weir J P (2005). Quantifying Test- Retest Reliability Using the Intraclass. Journal of 
Strength and Conditioning Research, 2005, 19(1), 231–240 2005 
Westerblad H, Allen D G, Lannergren J (2002). Muscle fatigue: lactic acid or inorganic 
phosphate the major cause? News Physiol Sci 17:17–21  
Zamora A J, Tessier F, Marconnet P, Margaritis I, Marini J F. (1995). Mitochondria 
changes in human muscle after prolonged exercise, endurance training and selenium 
supplementation. Eur J Appl Physiol Occup Physiol. 1995;71(6):505-11 
Zuniga J M, Housh T J, Camic C L, Hendrix C R, Schmidt R J, Mielke M and Johnson G 
O (2010). A mechanomyographic fatigue threshold test for cycling Int. J. Sports Med. 31 
636–43 
52 
VITA 
1. Quinnipiac University, BS in Athletic Training
2. Lauren Herrick, BS, ATC
